Micro- and nano-particles developed by electrohydrodynamic atomization for the sustained delivery of paclitaxel to treat C6 glioma

Jingwei Xie, Chi Hwa Wang

Research output: Contribution to conferencePaper

Abstract

This study aims to fabricate biodegradable polymeric particles by electrohydrodynamic atomization (EHDA) for applications in sustained delivery of anticancer drug - paclitaxel to treat C6 glioma. Controllable morphologies such as spheres, donut shape and corrugated shape with sizes from several tens of microns to hundred nanometers of particles were observed by scanning electron microscopy and field emission electron microscope. The differential scanning chromatography study indicated that paclitaxel could be either in an amorphous or disordered-crystalline phase of a molecular dispersion or a solid solution state in the polymer matrix after fabrication. The x-ray photon spectroscopy result suggested that some amount of paclitaxel could exist on the surface layer of the microparticles. The encapsulation efficiency was around 80% and more than 30 days in vitro sustained release profile could be achieved. Cell cycling results suggested that paclitaxel after encapsulation by EHDA could keep its biological function and inhibit C6 glioma cells in the G2/M phase. The cytotoxicity of paclitaxel-loaded biodegradable microparticles to C6 glioma cells could be higher than Taxol® in the long-term in vitro tests evaluated by MTS assay. The in vivo subcutaneous study suggested that 20% drug loading sample could inhibit C6 glioma tumour growth more effectively than Taxol® and there was no evident sign of systemic toxicity. The drug delivery devices developed by EHDA could be promising for the local drug delivery to treat malignant glioma.

Original languageEnglish (US)
Number of pages1
StatePublished - Dec 1 2005
Event05AIChE: 2005 AIChE Annual Meeting and Fall Showcase - Cincinnati, OH, United States
Duration: Oct 30 2005Nov 4 2005

Conference

Conference05AIChE: 2005 AIChE Annual Meeting and Fall Showcase
CountryUnited States
CityCincinnati, OH
Period10/30/0511/4/05

Fingerprint

Electrohydrodynamics
Atomization
Drug delivery
Encapsulation
Field emission microscopes
Cytotoxicity
Chromatography
Polymer matrix
Toxicity
Tumors
Solid solutions
Assays
Electron microscopes
Photons
Spectroscopy
Crystalline materials
Scanning
Fabrication
X rays
Scanning electron microscopy

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Xie, J., & Wang, C. H. (2005). Micro- and nano-particles developed by electrohydrodynamic atomization for the sustained delivery of paclitaxel to treat C6 glioma. Paper presented at 05AIChE: 2005 AIChE Annual Meeting and Fall Showcase, Cincinnati, OH, United States.

Micro- and nano-particles developed by electrohydrodynamic atomization for the sustained delivery of paclitaxel to treat C6 glioma. / Xie, Jingwei; Wang, Chi Hwa.

2005. Paper presented at 05AIChE: 2005 AIChE Annual Meeting and Fall Showcase, Cincinnati, OH, United States.

Research output: Contribution to conferencePaper

Xie, J & Wang, CH 2005, 'Micro- and nano-particles developed by electrohydrodynamic atomization for the sustained delivery of paclitaxel to treat C6 glioma', Paper presented at 05AIChE: 2005 AIChE Annual Meeting and Fall Showcase, Cincinnati, OH, United States, 10/30/05 - 11/4/05.
Xie J, Wang CH. Micro- and nano-particles developed by electrohydrodynamic atomization for the sustained delivery of paclitaxel to treat C6 glioma. 2005. Paper presented at 05AIChE: 2005 AIChE Annual Meeting and Fall Showcase, Cincinnati, OH, United States.
Xie, Jingwei ; Wang, Chi Hwa. / Micro- and nano-particles developed by electrohydrodynamic atomization for the sustained delivery of paclitaxel to treat C6 glioma. Paper presented at 05AIChE: 2005 AIChE Annual Meeting and Fall Showcase, Cincinnati, OH, United States.1 p.
@conference{91c04611a1fe4d77b4cfbac310f8f755,
title = "Micro- and nano-particles developed by electrohydrodynamic atomization for the sustained delivery of paclitaxel to treat C6 glioma",
abstract = "This study aims to fabricate biodegradable polymeric particles by electrohydrodynamic atomization (EHDA) for applications in sustained delivery of anticancer drug - paclitaxel to treat C6 glioma. Controllable morphologies such as spheres, donut shape and corrugated shape with sizes from several tens of microns to hundred nanometers of particles were observed by scanning electron microscopy and field emission electron microscope. The differential scanning chromatography study indicated that paclitaxel could be either in an amorphous or disordered-crystalline phase of a molecular dispersion or a solid solution state in the polymer matrix after fabrication. The x-ray photon spectroscopy result suggested that some amount of paclitaxel could exist on the surface layer of the microparticles. The encapsulation efficiency was around 80{\%} and more than 30 days in vitro sustained release profile could be achieved. Cell cycling results suggested that paclitaxel after encapsulation by EHDA could keep its biological function and inhibit C6 glioma cells in the G2/M phase. The cytotoxicity of paclitaxel-loaded biodegradable microparticles to C6 glioma cells could be higher than Taxol{\circledR} in the long-term in vitro tests evaluated by MTS assay. The in vivo subcutaneous study suggested that 20{\%} drug loading sample could inhibit C6 glioma tumour growth more effectively than Taxol{\circledR} and there was no evident sign of systemic toxicity. The drug delivery devices developed by EHDA could be promising for the local drug delivery to treat malignant glioma.",
author = "Jingwei Xie and Wang, {Chi Hwa}",
year = "2005",
month = "12",
day = "1",
language = "English (US)",
note = "05AIChE: 2005 AIChE Annual Meeting and Fall Showcase ; Conference date: 30-10-2005 Through 04-11-2005",

}

TY - CONF

T1 - Micro- and nano-particles developed by electrohydrodynamic atomization for the sustained delivery of paclitaxel to treat C6 glioma

AU - Xie, Jingwei

AU - Wang, Chi Hwa

PY - 2005/12/1

Y1 - 2005/12/1

N2 - This study aims to fabricate biodegradable polymeric particles by electrohydrodynamic atomization (EHDA) for applications in sustained delivery of anticancer drug - paclitaxel to treat C6 glioma. Controllable morphologies such as spheres, donut shape and corrugated shape with sizes from several tens of microns to hundred nanometers of particles were observed by scanning electron microscopy and field emission electron microscope. The differential scanning chromatography study indicated that paclitaxel could be either in an amorphous or disordered-crystalline phase of a molecular dispersion or a solid solution state in the polymer matrix after fabrication. The x-ray photon spectroscopy result suggested that some amount of paclitaxel could exist on the surface layer of the microparticles. The encapsulation efficiency was around 80% and more than 30 days in vitro sustained release profile could be achieved. Cell cycling results suggested that paclitaxel after encapsulation by EHDA could keep its biological function and inhibit C6 glioma cells in the G2/M phase. The cytotoxicity of paclitaxel-loaded biodegradable microparticles to C6 glioma cells could be higher than Taxol® in the long-term in vitro tests evaluated by MTS assay. The in vivo subcutaneous study suggested that 20% drug loading sample could inhibit C6 glioma tumour growth more effectively than Taxol® and there was no evident sign of systemic toxicity. The drug delivery devices developed by EHDA could be promising for the local drug delivery to treat malignant glioma.

AB - This study aims to fabricate biodegradable polymeric particles by electrohydrodynamic atomization (EHDA) for applications in sustained delivery of anticancer drug - paclitaxel to treat C6 glioma. Controllable morphologies such as spheres, donut shape and corrugated shape with sizes from several tens of microns to hundred nanometers of particles were observed by scanning electron microscopy and field emission electron microscope. The differential scanning chromatography study indicated that paclitaxel could be either in an amorphous or disordered-crystalline phase of a molecular dispersion or a solid solution state in the polymer matrix after fabrication. The x-ray photon spectroscopy result suggested that some amount of paclitaxel could exist on the surface layer of the microparticles. The encapsulation efficiency was around 80% and more than 30 days in vitro sustained release profile could be achieved. Cell cycling results suggested that paclitaxel after encapsulation by EHDA could keep its biological function and inhibit C6 glioma cells in the G2/M phase. The cytotoxicity of paclitaxel-loaded biodegradable microparticles to C6 glioma cells could be higher than Taxol® in the long-term in vitro tests evaluated by MTS assay. The in vivo subcutaneous study suggested that 20% drug loading sample could inhibit C6 glioma tumour growth more effectively than Taxol® and there was no evident sign of systemic toxicity. The drug delivery devices developed by EHDA could be promising for the local drug delivery to treat malignant glioma.

UR - http://www.scopus.com/inward/record.url?scp=33645638104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645638104&partnerID=8YFLogxK

M3 - Paper

AN - SCOPUS:33645638104

ER -